RTC
DNLI icon

Riverview Trust Company’s Denali Therapeutics DNLI Stock Holding History

Riverview Trust Company’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,171
Closed -$15.9K – 313
2025
Q1 		$15.9K Buy
+1,171
New +$22.4K 0.02% 520

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Riverview Trust Company's DNLI Position: Q2 2025 in Review

Riverview Trust Company sold out of Denali Therapeutics (DNLI) in Q2 2025, closing a stake of 1,171 shares — an estimated $15.9K sold.

Riverview Trust Company first reported a position in DNLI in Q1 2025 and held it in 1 quarter. The position peaked at $15.9K in Q1 2025. 230 funds tracked by Wall St. Rank hold DNLI as of Q2 2025.

  • Riverview Trust Company reported no remaining Denali Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Riverview Trust Company sold 1,171 Denali Therapeutics shares in Q2 2025, an estimated $15.9K.
  • Riverview Trust Company first reported a position in Denali Therapeutics in Q1 2025 and held it in 1 quarter.
  • Riverview Trust Company's Denali Therapeutics position peaked at $15.9K in Q1 2025.
  • 230 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2025.

Based on Riverview Trust Company's 13F filing for Q2 2025, filed 21 Jul 2025.